

早期のリスクファクター介入は洞調律を維持する (LBT Session, Abstract 1145)

RACE 3: リスクファクターに基づく心房細動のアップストリーム治療は洞調律維持率を改善する

RACE 3: Risk factor-driven upstream atrial fibrillation therapy improves sinus rhythm maintenance

早期の短時間持続する心房細動および心不全を有する患者において、リスクファクターに基づくアップストリーム治療によるリズムコントロールは、洞調律維持において有効で実行可能かつ安全である。このRACE 3トライアルの結果が2017 ESC Congress で発表された。この新たなアップストリーム療法は、きめ細かいリスクファクターの治療および生活習慣の改善などであった。この治療は、電気的除細動の少なくとも3週間前に開始され、12か月間継続された。1年後に洞調律であったのは、アップストリーム治療群の75%に対し、コントロール群では63%であった($p=0.021$)。抗不整脈薬使用や電気的除細動の回数は、2群間で差がなかった。

Full Text

Risk factor-driven upstream rhythm control is effective, feasible and safe in improving maintenance of sinus rhythm in patients with early short lasting atrial fibrillation (AF) and heart failure, according to late-breaking results from the RACE 3 trial presented in a Hot Line – LBCT Session at the 2017 ESC Congress. The novel therapy included meticulous treatment of risk factors and change of lifestyle and was superior to conventional guideline recommended rhythm control.

"Atrial fibrillation is the most common sustained cardiac arrhythmia and affects millions of people in Europe," said principal investigator Dr. Michiel Rienstra, cardiologist and clinical director of cardiology at the University Medical Centre Groningen, the Netherlands. "Patients suffer from palpitations, shortness of breath, impaired exercise tolerance, have poor quality of life and are at increased risk of stroke, heart failure or death."

In most patients, AF is in part caused by comorbidities such as hypertension, heart failure, and obesity. AF is a progressive disease and despite the available medical and interventional therapies, long-term maintenance of normal sinus rhythm is cumbersome. AF and its progression are caused by structural remodeling of the left atrium. Upstream rhythm control therapy may modify atrial remodeling and help prevent AF and its progression.

The RACE 3 trial was designed to test the hypothesis that risk factor driven upstream therapy is superior to conventional therapy for maintenance of sinus rhythm at 12 months in patients with early persistent AF and heart failure.

This international, investigator-initiated, multicenter, prospective, open label trial included 250 patients with symptomatic early persistent AF and early mild to moderate heart failure who were scheduled for electrical cardioversion. All patients received causal treatment of AF and heart failure and were then randomly allocated to conventional guideline recommended rhythm control with or without an additional four risk factor driven upstream therapies.

The upstream therapy group received: 1) cardiac rehabilitation including physical activity, dietary restrictions, and regular counselling on drug adherence, exercise maintenance and dietary restrictions; 2) mineralocorticoid receptor antagonists; 3) statins; and 4) angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers.

Upstream therapies started at least three weeks before electrical cardioversion and were continued for 12 months. Every effort was made to optimally titrate all drugs. If AF relapsed, repeat cardioversions, antiarrhythmic drugs and atrial ablation were allowed.

The primary endpoint was the presence of sinus rhythm after one year of follow-up, assessed with continuous seven day Holter monitoring during the last week of the study. Secondary endpoints included atrial size, left ventricular function, exercise capacity, hospitalizations for heart failure and other reasons, mortality, quality of life, and side effects of upstream therapies.

At one year follow-up, sinus rhythm was present in 89 of 119 (75%) patients in the upstream therapy group compared to 79 of 126 (63%) patients in the control group ($p=0.021$). There was no difference in antiarrhythmic drug use or the number of electrical cardioversions between the two groups.

Dr. Rienstra said: "Upstream rhythm control, including meticulous treatment of risk factors and change of lifestyle, is effective, feasible and safe in improving maintenance of sinus rhythm in patients with early short lasting AF and early mild to moderate heart failure. The upstream therapies also improved treatment of cardiovascular risk factors."

The trial was funded by grants from the Netherlands Heart Foundation and the Netherlands Heart Institute and by unrestricted educational grants from pharmaceutical and device companies.

The RACE 3 study is supported by grants to the Interuniversity Cardiology Institute Netherlands (now Netherlands Heart Institute) from the Dutch Heart Foundation, Interuniversity Cardiology Institute Netherlands, and University Medical Centre Groningen. In addition, unrestricted grants to the Interuniversity Cardiology Institute Netherlands (now Netherlands Heart Institute) by the following companies; Medtronic, Boehringer Ingelheim, Biotronik, St. Jude Medical (now Abbott), Boston Scientific, AstraZeneca, Sanofi-Aventis, Bayer.

Conference News

[News 01]

炎症を軽減することにより心血管系および肺がんのリスクが低下する

[News 02]

早期のリスクファクター介入は洞調律を維持する

[News 03]

LDLがどのように低下したかが重要

[News 04]

リパーロキサバンは心血管系および下肢のイベントを減少させる

[News 05]

塩分の過剰摂取は心不全リスクを倍増させる

[News 06]

短期間の抗血小板薬2剤併用療法は長期にわたり有効性を保つ

[News 07]

病院到着前の抗血小板療法の利点はない

[News 08]

PCIにおける最良の抗血小板薬2剤併用療法に疑問が投げかけられた

[News 09]

急性MIにおける酸素補充の死亡率に対する有益性はない

[News 10]

BMI低値はPCI後の予後不良につながる

[News 11]

黄砂と急性心筋梗塞

[News 12]

糖尿病性網膜症における強化スタチン療法の有益性に疑問が投げ掛けられた

[News 13]

トライアルの結果が腎除神経術の論議を再開させる

[News 14]

InclisiranはLDLコレステロールを最長1年間低下させる

[News 15]

睡眠の質の低下は心血管疾患につながる可能性がある

[News 16]

TAVIは90歳超の患者において安全かつ有効である

[News 17]

弁膜症を伴う残存肺高血圧症に対するシルデナフィルの効果は不良

[News 18]

高コレステロールは乳がんにおける死亡リスクを低下させる